



February 28, 2024  
JCR Pharmaceuticals Co., Ltd.

Translation

**Notice of Director’s Responsibility, Organizational and Personnel Changes**

February 28, 2024 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") hereby announces that its Board of Directors resolved at a meeting held today to change director’s responsibility, organizational and personnel changes as follows.

1. Director’s Responsibility Changes (As of April 1, 2024)

In order to further strengthen the global quality assurance system, the following duties of directors will be changed.

Name	New Area of Supervision	Current Area of Supervision
Yoshio Hiyama, Ph.D.	Senior Executive Director In charge of Quality Assurance Executive Director, Quality Assurance Div. and Director, Regulatory Affairs Dept.	Senior Executive Director In charge of Production and Quality Assurance Executive Director, Production Div.

2. Organizational Changes (As of April 1, 2024)

The New Global Business Operations Dept. is eliminated and its operation to be transferred within Corporate Strategy Div., to promote new global business operation linked with our corporate strategy. Moreover, the Corporate Communications/IR office is relocated from Administration Div. to Corporate Strategy Div. to strengthen our PR and IR activities to overseas.

3. Change of Corporate Officers (As of April 1, 2024)

Name	New Title	Current Title
Junichi Ando	Senior Corporate Officer In charge of Production Executive Director, Production Div.	Corporate Officer Executive Director, Quality Assurance Div. and Director, Regulatory Affairs Dept.
Yutaka Honda	Senior Corporate Officer In charge of Administration Executive Director, Administration Div. and Director, Human Resources Planning Dept.	Senior Corporate Officer In charge of Administration Executive Director, Administration Div. and Director, General Affairs Dept. and Director, Human Resources Planning Dept.

#### 4. Personnel Changes (As of April 1, 2024)

Name	New Title	Current Title
Yasunori Shiroyama	Director, Tokyo Metropolitan Area Sales Dept., Sales Div.	Director, Sales Div.
Tsuyoshi Tajiri	Director, Marketing Department., Sales Div.	Director, Tokyo Metropolitan Area Sales Dept., Sales Div.
Nobuyuki Tanaka	Senior Director, Product Div. and Director, Production Strategy Unit.	Director, Production Strategy Unit, Product Div.
Kenta Mizoguchi	Director, General Affairs Dept., Administration Div.	Manager, General Affairs Group General Affairs Dept., Administration Div.

#### **About JCR Pharmaceuticals Co., Ltd.**

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products News Release in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>

#### Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###